Stroke and Intracranial Hemorrhage in HeartMate II and HeartWare Left Ventricular Assist Devices: A Systematic Review
- PDF / 542,795 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 86 Downloads / 177 Views
ORIGINAL ARTICLE
Stroke and Intracranial Hemorrhage in HeartMate II and HeartWare Left Ventricular Assist Devices: A Systematic Review Sung M. Cho1 • Nader Moazami2 • Jennifer A. Frontera1
Ó Springer Science+Business Media New York 2017
Abstract Background Ischemic stroke and intracranial hemorrhage (ICH) following left ventricular assist device (LVAD) placement are major causes of morbidity. The incidence and mortality associated with these events stratified by device type have not been systematically explored. Methods A systematic review of PubMed was conducted from January 2007 through June 2016 for all English-language articles involving HeartMate II (HMII) and HeartWare LVAD patients. Ischemic stroke and/or ICH incidence (events per patient-year) and associated mortality rates were abstracted for each device type. Results Of 735 articles reviewed, 48 (11,310 patients) met inclusion criteria (33 HMII, six HeartWare, eight both devices, and one unspecified). The median duration of device support was 112 days (total 13,723 patient-years). Overall, ischemic stroke or ICH occurred in 9.8% (1110 persons and 0.08 events per patient year [EPPY]). Ischemic stroke occurred in a median of 6.0% or 0.06 EPPY (range 0–16% or 0–0.21 EPPY) of HMII patients versus 7.5% or 0.09 EPPY (range 4–17.1% or 0.01–0.94 EPPY) of HeartWare patients. ICH occurred in a median of 3.0% or 0.04 EPPY (range 0–13.5% or 0–0.13 EPPY) of HMII and 8.0% or 0.08 EPPY (range 3–23% or 0.01–0.56 EPPY) of
Electronic supplementary material The online version of this article (doi:10.1007/s12028-017-0386-7) contains supplementary material, which is available to authorized users. & Jennifer A. Frontera [email protected] 1
Department of Neurology, New York University, 150 55th St., Brooklyn, NY 11220, USA
2
Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA
HeartWare patients. The median mortality rate for LVADassociated ischemic stroke was 31% (HMII: 33%, [range 2.4–75%] and HeartWare: 11.5% [range 3.9–40%]), and the median mortality rate following ICH was 71% (HMII: 75%, [range 3.9–100%] and HeartWare: 44%, [range 3.1–88%]). Conclusions Ischemic stroke and ICH are common after LVAD placement, but heterogeneous event rates are reported in the literature. Given the high associated mortality, further prospective study is warranted. Keywords Left ventricular assisted device (LVAD) HeartWare (HVAD) HeartMate II (HMII) Ischemic stroke ICH
Introduction The number of patients with advanced stage heart failure refractory to maximal medical therapy has increased over the last decade, while the number of heart transplants has not kept pace. Due to these factors, the use of left ventricular assist devices (LVAD) as both a bridge to transplant (BTT) and a destination therapy (DT) has increased [1]. Although the two most commonly used LVADs, HeartMate II (HMII, Thoratec Corp., Pleasanton, CA) and HeartWare (HeartWare International Inc., Framingham, MA), are associated with better survival rates than firstgeneration LVADs, neurologica
Data Loading...
